DIVI'S LABORATORIES LIMITED |
Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
| 4,486 INR | +0.83% |
|
+4.16% | +14.92% |
| May. 31 | Indian Equities Close with Mild Gains on Friday, Helped by Financial, Telecom Stocks | MT |
| May. 29 | Indian Equities Dragged Down by Losses in Financial, IT Stocks | MT |
| Sales 2024 | 78.45B 941M | Sales 2025 * | 90.81B 1.09B | Capitalization | 1,181B 14.16B |
|---|---|---|---|---|---|
| Net income 2024 | 16B 192M | Net income 2025 * | 20.73B 248M | EV / Sales 2024 | 11.7 x |
| Net cash position 2024 * | 46.03B 552M | Net cash position 2025 * | 39.18B 470M | EV / Sales 2025 * | 12.6 x |
| P/E ratio 2024 |
57.2
x | P/E ratio 2025 * |
56.8
x | Employees | 8,433 |
| Yield 2024 * |
0.58% | Yield 2025 * |
0.66% | Free-Float | 47.76% |
More Fundamentals
* Assessed data
More news
Latest transcript on Divi's Laboratories Limited
More recommendations
More press releases
| 1 day | +1.17% | ||
| 1 week | +4.50% | ||
| Current month | +4.50% | ||
| 1 month | +15.07% | ||
| 3 months | +24.97% | ||
| 6 months | +20.53% | ||
| Current year | +15.29% |
1 week
4 180.50
4 525.00
1 month
3 724.004 525.00
Current year
3 350.004 525.00
1 year
3 295.304 525.00
3 years
2 730.005 425.10
5 years
1 466.005 425.10
10 years
532.655 425.10
| Managers | Title | Age | Since |
|---|---|---|---|
| Chief Executive Officer | 46 | 01-08-09 | |
| Founder | 73 | 90-10-11 | |
| Director of Finance/CFO | 74 | 94-11-19 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
| Founder | 73 | 90-10-11 | |
| Chief Executive Officer | 46 | 01-08-09 | |
| Director/Board Member | - | 14-06-22 |
| Name | Weight | AuM | 1st Jan change | Investor Rating |
|---|---|---|---|---|
| 0.68% | 6 M€ | +6.07% | - |
| Date | Price | Change | Volume |
|---|---|---|---|
| 24-06-07 | 4,486 | +0.83% | 211 761 |
| 24-06-06 | 4,449 | -1.19% | 790,310 |
| 24-06-05 | 4,503 | +4.13% | 1,077,221 |
| 24-06-04 | 4,324 | +0.05% | 847,809 |
| 24-06-03 | 4,322 | +0.34% | 515,368 |
Delayed Quote NSE India S.E., June 07, 2024 at 03:02 am EDT
More quotes
Divi's Laboratories Limited is specialized in the development and manufacture of active pharmaceutical ingredients, intermediates and nutraceutical ingredients.
Net sales by source of revenue break down into product sales (97.9%) and service sales (2.1%).
At the end of March 2020, the group has 2 production sites located in India.
Sector
Pharmaceuticals
Calendar
2024-08-11
- Q1 2025 Earnings Release (Projected)
Trading Rating
Investor Rating
ESG Refinitiv
B
Sell
Buy
Mean consensus
HOLD
Number of Analysts
27
Last Close Price
4,449
INR
Average target price
3,871
INR
Spread / Average Target
-12.98%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| +15.29% | 14.15B | |
| +43.64% | 754B | |
| +39.56% | 630B | |
| -6.58% | 352B | |
| +19.72% | 331B | |
| +8.78% | 298B | |
| +12.16% | 217B | |
| -2.25% | 216B | |
| +0.03% | 163B | |
| +6.13% | 164B |
- Stock Market
- Equities
- DIVISLAB Stock
